• Misbah Tahir, Khalid Mustafa, Muhammad Ali, and Danial Khalid.
• Misbah Tahir, FCPS Department of Radiology, Liaquat National Hospital, National Stadium Road, Karachi, Pakistan.
• Pak J Med Sci. 2024 Jul 1; 40 (6): 119612001196-1200.

ObjectiveTo assess the overall survival in patients with intermediate stage hepatocellular carcinoma following transarterial chemoembolization.MethodsIt is a retrospective descriptive study carried out in the Department of Radiology of Liaquat National Hospital Karachi, Pakistan. Seventy-two patients were enrolled from July 2014 to December 2021 and had chemoembolization therapy. Patients were followed till their demise. Mean and Median survivals were calculated.ResultsA total of 72 patients had a median survival of 15 months with 95% confidence interval (11 months was lower bound and 18 months was upper bound), 19 months was the mean survival time with 95% confidence interval (14.7 months was lower limit and 22.6 months the upper limit). The factors which had a significant impact on the median survival time were Child-Pugh classification, average size of tumor and embolization pattern.ConclusionTransarterial chemoembolization (TACE) increases the median survival time effectively and safely in patients with hepatocellular carcinoma. However complete resolution of disease is not possible with TACE, with most patient eventually succumbing to the disease. The overall survival for TACE in this study correlates well with other studies. Child Pugh Class, tumor size and embolization pattern have significant effect on survival of patients.Copyright: © Pakistan Journal of Medical Sciences.

4 keywords...

hide…